Researchers at IDIBELL-ICO describe a new resistance mechanism

July 02, 2019

Researchers at IDIBELL-ICO describe a new resistance mechanism to therapies that prevent the formation of blood vesselsResearchers at the Bellvitge Biomedical Research Institute (IDIBELL) and the ProCure Program of the Catalan Institute of Oncology (ICO) published today at Cancer Research a study describing a new mechanism in cancer that turns cells into malignant cells and contradicts what had been published so far about drug resistance that prevent the formation of blood vessels (anti-angiogenics). The research has been led by Dr. Oriol Casanovas, from the group of Tumor Angiogenesis of the IDIBELL, and the Dra. Iratxe Zuazo has participated as one of the first authors.

In the search for alternative factors to fight cancer, antibody development as a therapeutic route is one of them. Antibodies can have an anti-tumor effect, preventing tumors from developing properly. In this study, scientists observed that one of these antibodies led to similar effects to those known for traditional antiangiogenic medications. However, the initial response to treatment culminated in the appearance of long-term resistance and malignancy through a mechanism unknown to date.

"In the formation of blood vessels (angiogenesis) it had been described that the conditions of low oxygen concentration (hypoxia) in the tumor were the cause of malignization of the tumor cells that became more aggressive and migrated" says Dr. Iratxe Zuazo, "but our samples did not present hypoxia conditions and we still had this effect".

The antibody of the study had the target Semaphorin 4D (Sema4D). Semaphorins are a large and diverse family of proteins from outside the cells, involved in cell signaling, and are essential for the development and maintenance of many organs and tissues. Some of them have implications for angiogenesis and cancer progression. Its name comes from the Greek semaphero, that means "bearer of signals".

Sema4D is a protein that is expressed predominantly in the membrane of solid tumors, in cancers such as breast, prostate and colon cancer. This protein is also found in tumor-associated macrophages (TAMs), which are immune cells that play an important role in tumor invasion, tumor formation and in metastasis. The 4D Semaphorin is also related to the formation of blood vessels.

Faced with this new situation, the researchers looked for which could be the differential factor from what was known to date, and they realized that there was a large presence of macrophages. They saw that, in the presence of the anti-Sema4D antibody, the macrophages secreted a molecule named SDF1, which causes the tumor cells to migrate more: they present more motility and more invasion.

These tests were done in transgenic mice models and what was observed was an increased survival of animals in the short term. In the long term, however, an unwanted effect (metastasis) was generated, significantly worsening the condition of the mice.

"Now that we know the new mechanism, we can begin to look for a way to inhibit it - for example, avoiding secretion of SDF1- and, in this way, to give an alternative to only have the positive effects of the antibody" explains Dr. Oriol Casanovas. He adds that "depending on each case, treatments could be carried out simultaneously with two drugs at the same time".

"What we propose is that the immune system is also taken into account when doing some therapies, because now we know that there may be the possibility of activating it with some drugs", concludes Dr. Iratxe Zuazo.
-end-


IDIBELL-Bellvitge Biomedical Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.